posted on 2024-10-30, 15:31authored byBehdokht Bahrami, Mousa Mohammadnia-Afrouzi, Peyman Bakhshaei, Yaghoub Yazdani, Ghasem Ghalamfarsa, Mehdi Yousefi, Sanam Sadreddini, Farhad Jadidi-Niaragh, Mohammad Hojjat-Farsangi
The selective and efficient drug delivery to tumor cells can remarkably improve different cancer therapeutic approaches. There are several nanoparticles (NPs) which can act as a potent drug carrier for cancer therapy. However, the specific drug delivery to cancer cells is an important issue which should be considered before designing new NPs for in vivo application. It has been shown that cancer cells over-express folate receptor (FR) in order to improve their growth. As normal cells express a significantly lower levels of FR compared to tumor cells, it seems that folate molecules can be used as potent targeting moieties in different nanocarrier-based therapeutic approaches. Moreover, there is evidence which implies folate-conjugated NPs can selectively deliver anti-tumor drugs into cancer cells both in vitro and in vivo. In this review, we will discuss about the efficiency of different folate-conjugated NPs in cancer therapy.